Industry Veteran Brings Depth of Oncology Clinical Development and Leadership Experience
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, today announced the appointment of Elizabeth Trehu, M.D., to the position of chief medical officer. Dr. Trehu brings to Jounce more than 25 years of clinical experience, including nearly 15 years in the biotech industry leading translational and integrated hematology and oncology drug development.
"We are thrilled to welcome Beth to the Jounce team at this exciting time for the company," said Richard Murray, Ph.D., chief executive officer of Jounce. "Beth's experience moving investigational products through clinical development, as well as her leadership experience in both biotech and academia, will be invaluable to Jounce as we advance our lead ICOS program, JTX-2011, into the clinic, and prepare additional immunotherapies for IND-enabling studies."
Dr. Trehu joins Jounce from Promedior, Inc., where she served as the chief medical officer. In this role, she was responsible for clinical development, clinical operations, regulatory affairs, quality assurance and program management, and led the creation and implementation of clinical development plans for Promedior's lead product candidate. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme's transplant oncology group. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE®. As an assistant professor of medicine at Tufts University School of Medicine, Dr. Trehu conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group. Prior to that, she was an internal medicine resident and chief resident at Georgetown University School of Medicine, where she also ran the transitional residency program. Dr. Trehu received her A.B. in English Literature from Princeton University and her M.D. from New York University School of Medicine.
"I began my career working in the now rapidly evolving field of immuno-oncology, and believe it is a truly revolutionary approach to the treatment of cancer," said Dr. Trehu. "Jounce's unique, translational science approach sets them apart within the industry, and I'm delighted to join the company as we prepare to move our first product into clinical trials. With differentiated science and a team of industry leaders, we have an opportunity to make a tremendous impact on the lives of patients with cancer."
About Jounce Therapeutics
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce integrates translational science insights to select the right targets and patient populations leading to clinical trials with higher probability of success and rapid proof-of-concept. The company is advancing programs that leverage contributions from its world-class founders as well as knowledge acquired from Jounce's translational science platform to create a sustainable "discovery to human proof-of-concept" product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.
Pure Communications, Inc.
Dan Budwick, 973-271-6085